Subscribe To
Ora, inc. and blindcan film festival unveil the blind canvas project using ai to visualize the human experience of blindness
Stories, art, and artificial intelligence cultivate awareness andcelebrate individuals living with visual impairments A Media Snippet accompanying thi...
November 3, 2023, 12:00 pm
Pantheon vision raises $2.5 million in seed funding to launch development of bioengineered corneal implant
The medical device startup is focused on addressing significant unmet needs of patients suffering from corneal ...
November 2, 2023, 6:06 pm
Cvs, target and other eye-drop products pose risk of dangerous infections, fda warns
More than two dozen over-the-counter eye-drop products marketed under CVS Health Corp. CVS, +1.40%, Target Corp. TGT, +1.15%, Rite Aid Corp. RADCQ, +8...
October 30, 2023, 12:10 pm
3 gene editing stocks to generate super-charged gains
Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroduc...
October 18, 2023, 11:05 am
Pakistan bans roche cancer drug pending probe into patients' blindness
Pakistan's drug regulator said on Monday it had temporarily banned the use of a cancer medication distributed by Swiss pharmaceutical company Roche pe...
September 25, 2023, 5:20 am
Regeneron drops as us fda declines to approve higher-dose version of its eye disease treatment
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) shares plummeted by nearly 9% in after-hours trade on Tuesday after the US Food and Drug Administration...
June 28, 2023, 8:51 am
Ai-based health screening company ihealthscreen reaches $150k in investments
iHealthScreen is an AI-driven, HIPAA-compliant medtech company with incoming product traction in several international markets, using AI to scalably s...
June 27, 2023, 12:25 am
Astellas pharma ceo says confident of iveric bio drug approval
Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a de...
May 1, 2023, 8:58 pm
Fda approves syfovre™ (pegcetacoplan injection) as the first and only treatment for geographic atrophy (ga), a leading cause of blindness
SYFOVRE slowed GA progression with increasing effects over time Approved for all patients with GA, with dosing flexibility every 25 to 60 days Well-de...
February 17, 2023, 9:06 pm
Eylea® (aflibercept) injection approved as the first pharmacologic treatment for preterm infants with retinopathy of prematurity (rop) by the fda
ROP is a leading cause of childhood blindness worldwide EYLEA now approved to treat five retinal condit...
February 8, 2023, 11:45 pm
Apellis pharmaceuticals advances as us regulator approves new drug application (nda) amendment for geographic atrophy (ga) therapy
Apellis Pharmaceuticals Inc (NASDAQ:APLS) shares surged in pre-market deals after the Nasdaq-listed global biopharma announced that the US regulator ...
November 18, 2022, 10:04 am
Ocugen, inc. to present at the 34th annual roth conference
MALVERN, Pa., March 09, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a clinical-stage biopharmaceutical company focused on discovering, devel...
March 9, 2022, 7:11 am
Ocugen to host conference call on friday, february 25 at 8:30 a.m. et to discuss fourth quarter and full year 2021 financial results and provide business update
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comme...
February 18, 2022, 6:12 pm
Ocugen to host conference call on friday, february 25 at 8:30 a.m. et to discuss fourth quarter and full year 2021 financial results and provide business update
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comme...
February 18, 2022, 6:12 pm
Ocugen to host conference call on friday, february 25 at 8:30 a.m. et to discuss fourth quarter and full year 2021 financial results and provide business update
MALVERN, Pa., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comme...
February 18, 2022, 6:12 pm